Entasis Therapeutics Initiates Global Phase 3 Pivotal Trial of ETX2514SUL for Patients with Carbapenem-Resistant Acinetobacter Infections Read more about Entasis Therapeutics Initiates Global Phase 3 Pivotal Trial of ETX2514SUL for Patients with Carbapenem-Resistant Acinetobacter Infections
MacroGenics Presented Preclinical Data about Margetuximab at the AACR Annual Meeting 2019 Read more about MacroGenics Presented Preclinical Data about Margetuximab at the AACR Annual Meeting 2019
Novocure Initiates Phase 3 Pivotal Trial in Recurrent Ovarian Cancer Read more about Novocure Initiates Phase 3 Pivotal Trial in Recurrent Ovarian Cancer
New England Journal of Medicine Publishes Results from Pivotal Phase 3 Studies of Paratek’s NUZYRA™ (Omadacycline) For Pneumonia and Skin Infections Read more about New England Journal of Medicine Publishes Results from Pivotal Phase 3 Studies of Paratek’s NUZYRA™ (Omadacycline) For Pneumonia and Skin Infections
MacroGenics Announces Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab Read more about MacroGenics Announces Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab
Entasis Therapeutics Receives Positive Feedback from FDA End-of-Phase 2 Meeting for ETX2514SUL; Signs Rapid Diagnostic Agreement with bioMérieux Read more about Entasis Therapeutics Receives Positive Feedback from FDA End-of-Phase 2 Meeting for ETX2514SUL; Signs Rapid Diagnostic Agreement with bioMérieux
Updated Clinical Data from Combination of Margetuximab and Pembrolizumab in Gastric Cancer Presented at 2019 ASCO Gastrointestinal Cancers Symposium Read more about Updated Clinical Data from Combination of Margetuximab and Pembrolizumab in Gastric Cancer Presented at 2019 ASCO Gastrointestinal Cancers Symposium
Five Prime Therapeutics Presents Data from Safety Lead-in to Phase 3 FIGHT Trial of Bemarituzumab at 2019 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium Read more about Five Prime Therapeutics Presents Data from Safety Lead-in to Phase 3 FIGHT Trial of Bemarituzumab at 2019 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium
Paratek Announces FDA Approval of NUZYRA™ (Omadacycline) Read more about Paratek Announces FDA Approval of NUZYRA™ (Omadacycline)